The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific instrument originally developed to describe and monitor health status in patients with heart failure. [12] [13] [14] The KCCQ integrates patients' symptoms, functional status, and quality of life into a single measure and has been shown to predict mortality in various heart failure populations 15 and has also been shown to be prognostically significant in patients with medically managed aortic stenosis. 16 To date, however, the association of the KCCQ with mortality after TAVR has not been evaluated. If health status is an independent prognostic risk factor for patients with TAVR, its inclusion in risk models seeking to compare the quality of TAVR across centers would enhance the fairness and quality of these efforts. To determine whether preprocedure health status is associated with survival after TAVR, we used data from the Society of Thoracic Surgeons (STS)/ American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry to examine whether baseline KCCQ scores are associated with short-and long-term mortality after TAVR.
Methods

Study Sample and Protocol
Details of the design, structure, and data elements for the TVT Registry have been previously published. 17, 18 In brief, the registry is a joint initiative of the STS and ACC and was launched in 2011, following Food and Drug Administration approval of the Sapien Transcatheter Heart Valve. The TVT Registry was originally developed in response to the Centers for Medicare and Medicaid Services requirement for national registry participation of all TAVR centers and now includes >300 clinical sites. Registry activities have been approved by a central institutional review board, and the Duke University School of Medicine institutional review board granted a waiver of informed consent for this study. Participating sites collect data on patient demographics, comorbidities, hemodynamics, functional status, patient-reported health status, and outcomes. Data quality is maintained through site training and supported by TVT Registry staff, data integrity checks by the analytic centers, auditing portions of data at the site level, and adjudication of selected 30-day and 1-year outcomes. The TVT Registry has been linked to Medicare administrative claims using direct patient identifiers by the Centers for Medicare and Medicaid Services to evaluate long-term patient outcomes, including hospitalizations and survival.
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Health Status Assessment
The KCCQ is a patient-reported disease-specific health status survey originally developed to describe and monitor health status in patients with heart failure. 12 The KCCQ has undergone extensive reliability and validity testing in various heart failure populations, 12, 20 as well as those with severe aortic stenosis. 16 Recently, a 12-item version of the KCCQ has been developed and found to be psychometrically valid, 21 and this version was collected in the TVT Registry. For this study, we focused on the overall summary score of the KCCQ-12, which ranges from 0 to 100 with higher scores indicating less symptom burden, less physical and social limitations, and better quality of life. Linguistically and culturally validated translations of the KCCQ were provided to non-English speakers. As in previous work, we categorized the KCCQ overall summary score as very poor health status (KCCQ <25), poor (KCCQ 25-49), fair (KCCQ 50-74), and good (KCCQ ≥75).
15,16
Statistical Analysis
Baseline characteristics and in-hospital outcomes were compared across health status groups using the Cochran-Armitage test for categorical variables and the Jonckheere-Terpstra test for continuous variables. The mortality risk of the patients was estimated using STS Predicted Risk of Operative Mortality score, which includes 24 variables and has been validated for predicting mortality from surgical aortic valve replacement. 22 The association of health status with mortality over the year after TAVR was assessed with the KaplanMeier method and log-rank test (for unadjusted comparisons) and Cox proportional hazards models (for risk-adjusted comparisons). Covariates in our adjusted model were selected from a recently developed TVT risk-adjustment model for in-hospital mortality and included age, body surface area, sex, race, estimated glomerular filtration rate, left ventricular ejection fraction, hemoglobin, platelet count, left main coronary artery stenosis ≥50%, proximal left anterior descending artery stenosis, prior myocardial infarction, current dialysis, endocarditis, prior transient ischemic attack, prior stroke, carotid stenosis, peripheral artery disease, current smoker, diabetes mellitus, atrial fibrillation or flutter, conduction defects, severe chronic lung disease, home oxygen, hostile chest, porcelain aorta, access site (femoral versus other), permanent pacemaker, implantable defibrillator, prior percutaneous coronary intervention, prior coronary artery bypass graft surgery, prior cardiac operations (2 or more versus 1 versus 0), prior aortic procedure, prior nonaortic procedure, aortic stenosis cause (degenerative versus other), valve morphology (tricuspid versus other), aortic insufficiency (moderate/severe versus other), mitral insufficiency (moderate/severe versus other), tricuspid
WHAT IS KNOWN
• One-year mortality after transcatheter aortic valve replacement (TAVR) remains high and challenging to predict.
• The Kansas City Cardiomyopathy Questionnaire is a health status measure that integrates patients' symptoms, functional status, and quality of life into a single measure-factors that could be associated with mortality after TAVR.
WHAT THE STUDY ADDS
• Among 7769 patients from 286 sites in the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry, we found that the majority of patients who underwent commercially available TAVR in the United States between 2011 and 2014 had poor or very poor preprocedure disease-specific health status.
• Worse health status at baseline was associated with a greater risk of in-hospital and 1-year mortality, although event rates among those with even the worst pre-TAVR health status were not high enough to consider poor health status, in isolation, a contraindication for TAVR.
• Because the Kansas City Cardiomyopathy Questionnaire is reliable, patient-centered, and easily collected in routine clinical practice, we think that these findings support the measurement and integration of the Kansas City Cardiomyopathy Questionnaire into mortality risk assessments for TAVR and should encourage the continued collection of these data as a part of the TVT Registry and as a part of the routine evaluation of TAVR.
insufficiency (moderate/severe versus other), and patient acuity (urgent versus shock/inotropes/assist device versus emergency/salvage/ cardiac arrest).
The characteristics of patients with missing baseline KCCQ data were compared with those in the analytic cohort using the χ 2 test for categorical variables and the Mann-Whitney test for continuous variables. Unadjusted and adjusted mortality were compared between groups using similar methods as above (log-rank test and Cox proportional hazards models, respectively). There were modest differences in baseline characteristics and outcomes between those with and without missing KCCQ data (Table I in the Data Supplement). For the purposes of sensitivity analysis, missing independent variable data were assumed to be missing at random conditional on observed patient demographic and clinical factors and outcomes. We estimated baseline missing KCCQ data using sequential regression modeling and 20 imputed data sets. 23 The models were rerun on the imputed data sets, and the results were pooled. All analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC), and statistical significance was defined as a 2-sided P value of <0.05.
Results
Study Sample
Between November 2011 and June 2014, a total of 15 938 patients aged ≥65 years underwent TAVR at 304 sites and were included in the TVT Registry. We excluded 3756 patients, who were unable to be linked to Medicare claims data, resulting in an eligible cohort of 12 182 patients. After further excluding 4413 (36%) patients, who were missing baseline KCCQ data, our final analytic cohort included 7769 patients who were enrolled at 286 sites ( Figure 1 ). Patients with missing baseline KCCQ data tended to be sicker than those in the analytic cohort, with more lung disease, more kidney disease, higher STS mortality risk scores, and were more likely to be considered inoperable or prohibitive surgical risk (Table I in the Data Supplement). Over the 12 months after TAVR, patients with missing baseline KCCQ were also more likely to die when compared with those in the analytic cohort, with unadjusted mortality rates of 26.3% versus 21.8%, respectively (P<0.001; Figure in the Data Supplement). This increased hazard of death among those patients with missing data remained after multivariable adjustment (adjusted hazard ratio, 1.21; 95% confidence interval, 1.10-1.34).
Median age for the analytic cohort was 84 years, 47% were men, 31% had a prior coronary artery bypass graft surgery, 34% had diabetes mellitus, and 13% were on home oxygen. Median STS mortality risk score was 7.0 (Q1-Q3, 4.7-10.6); median mean aortic gradient was 43 mm Hg; and 51% underwent TAVR via a femoral approach. Before TAVR, the median KCCQ score was 37.5 (Q1-Q3, 22.4-56.8), and health status was rated as very poor in 28%, poor in 38%, fair in 24%, and good in 10%. The baseline characteristics of the 4 groups are shown in Table 1 . Patients with poorer baseline health status were more likely to be women and were more likely to have lung disease, kidney disease, and diabetes mellitus. Poorer health status was also associated with longer times on the 5-m walk test, lower mean aortic valve gradients, more moderate or severe mitral regurgitation, and higher estimated surgical mortality risk (per the STS mortality risk score).
In-Hospital Outcomes
Poorer health status was associated with a more prolonged hospital stay and an increased risk of death after TAVR (Table 2 ). In-hospital mortality was strongly associated with baseline health status, ranging from 6.2% among those with very poor health status to 2.8% among those with good health status (P<0.001 for test of trend). Worse baseline health status was also associated with an increased likelihood of new dialysis during the index hospitalization (P<0.001 for test of trend). Health status was not associated with the risk of other in-hospital complications. Length of stay was longer, both in the intensive care unit and in the hospital overall, for patients with poorer health status, and among those who survived the hospitalization, patients with poorer health status were less likely to be discharged to home.
Long-Term Outcomes
Poorer health status before TAVR was associated with an increased risk of mortality after the procedure-a difference that emerged early and continued to increase throughout the first year of follow-up. One year after TAVR, 29% of patients with very poor baseline health status had died when compared with 22% with poor health status, 17% with fair health status, and 14% with good health status (P<0.001; Figure 2 ). After adjustment for multiple demographic and clinical characteristics, poorer health status before TAVR continued to be associated with an increased hazard of death after TAVR. After multivariable risk-adjustment, compared with those with good health status before TAVR, patients with very poor health status had a 2-fold increased hazard of death over the first year after TAVR (adjusted hazard ratio, 2.00; 95% confidence interval, 1.58-2.54), whereas those with poor and fair health status had intermediate outcomes (adjusted hazard ratio, 1.54; 95% confidence interval, 1.22-1.95 and adjusted hazard ratio, 1.20; 95% confidence interval, 0.94-1.55, respectively). In the sensitivity analysis where missing baseline KCCQ data were imputed, the results were consistent with the main analysis (Table II in the Data Supplement).
Discussion
In this large, multicenter cohort of contemporary clinical practice, we found that the majority of patients who underwent commercially available TAVR in the United States between 2011 and 2014 had poor or very poor preprocedure diseasespecific health status. Patients with poorer baseline health status tended to have more comorbidities, higher estimated mortality risk, and worse mobility. Worse health status at baseline was associated with a greater risk of in-hospital and 1-year mortality, even after extensive adjustment for demographic and clinical characteristics. Nonetheless, even among patients with the worst health status before TAVR, over 70% were still alive at 1 year after their procedure, indicating that poor health status before TAVR should not, in isolation, be considered a contraindication for TAVR. This is a particularly important finding, as a high burden of heart failure symptoms that greatly affect quality of life is often a primary indication for TAVR. Finally, these results support the measurement and integration of the KCCQ into mortality risk assessments for TAVR and should encourage the continued collection of these data as a part of the TVT Registry and other similar quality improvement and quality assurance efforts.
The results of this study both support and extend prior research on the prognostic importance of patient health status metrics in cardiovascular populations. In patients with systolic heart failure, several previous studies have shown that lower KCCQ scores are associated with a greater risk of long-term mortality. 11, 13, 15, 24 For example, in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), 18% of patients with a KCCQ score <25 at 1 month post myocardial infarction had died by 1 year when compared with 6% of patients with a KCCQ score ≥75. 15 The prognostic importance of heart failure-specific health status has also been shown among patients with severe aortic stenosis. In the Placement of Aortic Transcatheter Valve (PARTNER) Trial, among medically managed patients with severe aortic stenosis, nearly 75% of patients with baseline KCCQ score ≤25 were dead by 1 year when compared with only ≈30% of patients with KCCQ score >50. 16 In contrast, preprocedure KCCQ has not been found to predict mortality in patients with heart failure treated with left ventricular assist devices. 25, 26 However, there are several potential reasons for the discrepancy between our data and those observed in the left ventricular assist device patient population. First, left ventricular assist devices are often implanted when the patient is acutely ill and in cardiogenic shock. In these situations, KCCQ scores are acutely depressed and may not accurately reflect the chronic heart failure symptoms and functional capacity of the patient. This situation is in contrast to that for TAVR, which is rarely performed emergently. Second, left ventricular assist devices are associated with several late complications and adverse events, such as gastrointestinal bleeding, stroke, and infections, that affect subsequent mortality to a much greater degree than after TAVR. 27 Prior work exploring factors associated with mortality after TAVR supports the hypothesis that the KCCQ would be prognostically important. Reduced functional capacity, as assessed using a 6-minute walk test, has been shown to be a strong correlate of mortality after TAVR. 7, 8 Unfortunately, the 6-minute walk test can be cumbersome to complete in the clinic and, even more so, in the hospital. In addition, many patients who are being considered for TAVR have additional disabilities that may limit their ability to complete a 6-minute walk test, independent of their cardiovascular status. The KCCQ, as a patient-reported questionnaire, is straightforward to administer both in the outpatient and inpatient setting, assesses functional capacity, and has been shown to retain much of the predictive ability of objective functional assessments. 28 In addition to functional capacity, the KCCQ assesses the severity of heart failure symptoms, which has also been shown to be prognostically important in the form of NYHA class. However, the NYHA class is a coarse assessment of symptoms when compared with the KCCQ, which limits its ability to discriminate between patients. 10, 11 Furthermore, because NYHA class is assigned by the physician and not by the patient, there is the potential for misclassification of symptoms. For example, in our data set, 10% of patients with KCCQ score <25 were rated as NYHA class I to II by their physician, whereas 67% of patients with KCCQ score ≥75 were classified as NYHA class III to IV (Table III in the Data Supplement) . Prior studies in patients with coronary artery disease have also shown substantial discordance between patient-reported and physician-assessed symptoms. 29 Although additional studies are needed to further define the discrepancy between physician-assessed and patient-assessed health status in patients undergoing TAVR, we hypothesize that using a validated instrument to assess symptoms and functional status directly from the patient provides much greater reliability, and thus greater predictive ability, when compared with more indirect assessments. Patient-reported outcomes are increasingly a focus of measurement in the healthcare system, which is likely only to increase as healthcare reform evolves. The KCCQ has established value in the setting of TAVR (a procedure designed not only to improve survival but also to improve quality of life)-quantifying the patient's response to therapy, enabling the comparison of new devices as technologies advance, and ensuring appropriate patient selection (through responder analyses). However, our data demonstrate that the KCCQ also has value as a correlate of subsequent outcomes at the time of TAVR-improving risk adjustment for mortality beyond a model that included 39 demographic, clinical, and echocardiographic variables. These results highlight the value of measuring the KCCQ in these patients, both preprocedurally (to risk stratify) and through follow-up (to monitor response to therapy).
Limitations
This study has several potential limitations that warrant further discussion. First, a substantial proportion of patients were missing baseline health status data. Before TAVR, these patients tended to be sicker and at higher risk for morbidity and mortality. They were also more likely to die in the year after TAVR when compared with patients who completed the KCCQ. We attempted to address this limitation by performing a sensitivity analysis with imputation of missing baseline KCCQ data. As expected, after imputation, the proportion of patients with low and very low KCCQ scores at baseline increased. However, the relationship between the KCCQ and mortality was not materially altered by inclusion of these patients with missing data. Second, as part of the TVT registry, the KCCQ is also collected in follow-up after TAVR. However, at this time, follow-up health status data are missing in a large proportion of patients, precluding meaningful examination of this important additional end point. Given the importance of improved health status as a goal of TAVR, future studies are needed to explore this outcome. Finally, as with any observational analysis, there is a possibility for residual confounding. We attempted to mitigate this risk through extensive adjustment for demographic and clinical characteristics. Furthermore, our results are consistent with prior studies demonstrating the predictive value of patient health status in other populations, thereby increasing our confidence in the validity of our results.
Conclusions
Patient-reported health status, as assessed by the KCCQ, is substantially impaired among US patients undergoing TAVR. Moreover, worse preprocedure health status is associated with an increased risk of in-hospital and 1-year mortality after TAVR, even after adjusting for an extensive list of demographic and clinical characteristics. These findings demonstrate the importance of reliably assessing patient-reported symptoms and functional capacity before TAVR to best risk stratify patients and improve prediction and communication of long-term risks. Because the KCCQ is reliable, patient-centered, and easily collected in routine clinical practice, we think that these findings should encourage the continued collection of the KCCQ as a part of the routine evaluation of TAVR patients. Future work is needed to examine the value of the KCCQ for predicting outcomes that integrate survival and quality of life.
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